1110 related articles for article (PubMed ID: 20855822)
21. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
Talpur R; Singh L; Daulat S; Liu P; Seyfer S; Trynosky T; Wei W; Duvic M
Clin Cancer Res; 2012 Sep; 18(18):5051-60. PubMed ID: 22850569
[TBL] [Abstract][Full Text] [Related]
22. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
23. [Prognosis of primary cutaneous lymphomas].
Grange F; Bagot M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927
[TBL] [Abstract][Full Text] [Related]
24. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
Desai M; Liu S; Parker S
J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
[TBL] [Abstract][Full Text] [Related]
26. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
[TBL] [Abstract][Full Text] [Related]
28. A modified staging classification for cutaneous T-cell lymphoma.
Kashani-Sabet M; McMillan A; Zackheim HS
J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
[TBL] [Abstract][Full Text] [Related]
29. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
30. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
Tancrède-Bohin E; Ionescu MA; de La Salmonière P; Dupuy A; Rivet J; Rybojad M; Dubertret L; Bachelez H; Lebbé C; Morel P
Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
[TBL] [Abstract][Full Text] [Related]
32. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
33. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.
Vermeer MH; Geelen FA; Kummer JA; Meijer CJ; Willemze R
Am J Pathol; 1999 Apr; 154(4):1203-10. PubMed ID: 10233858
[TBL] [Abstract][Full Text] [Related]
34. [Clinicomorphological characteristics of Sezary's disease and mycosis fungoides].
Vinogradova IuE; Giliazitdinova EA; Zamulaeva IA; Zybunova EE; Kaplanskaia IB; Kravchenko SK; Kremenetskaia AM; Lutsenko IN; Samoĭlova RS; Selivanova EN; Sidorova IuV; Shklovskiĭ-Kord NE
Ter Arkh; 2005; 77(10):61-5. PubMed ID: 16320688
[TBL] [Abstract][Full Text] [Related]
35. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
36. Folliculotropic mycosis fungoides (stage IIA) progressing to Sézary syndrome: a case report.
Agar N; Whittaker SJ
Br J Dermatol; 2008 Nov; 159(5):1197-9. PubMed ID: 18764843
[TBL] [Abstract][Full Text] [Related]
37. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
38. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group.
Senff NJ; Willemze R
Br J Dermatol; 2007 Dec; 157(6):1205-11. PubMed ID: 17941944
[TBL] [Abstract][Full Text] [Related]
39. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
40. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]